Medopad offers Covid-specific remote patient monitoring

Chloe Kent 26 March 2020 (Last Updated March 26th, 2020 11:14)

British healthtech company Medopad is offering support to the global healthcare sector by providing clinicians with a specialised Covid-19 version of its remote patient monitoring (RPM) platform. The technology will be available for NHS Trusts across the UK as well as global healthcare providers.

Medopad offers Covid-specific remote patient monitoring
Medopad’s software is CE marked and under FDA enforcement discretion. Credit: Shutterstock

British healthtech company Medopad is offering support to the global healthcare sector by providing clinicians with a specialised Covid-19 version of its remote patient monitoring (RPM) platform. The technology will be available for NHS Trusts across the UK as well as global healthcare providers.

Medopad has worked with Imperial College, Guys’ and St Thomas’ NHS Foundation Trust, as well as Johns Hopkins University to create the specialist Covid-19 RPM platform. It is designed to help monitor ill and at-risk patients, enable care for chronically ill patients and provide insights into the operations of healthcare systems to help them prioritise resources and respond more effectively.

Using Medopad’s RPM app and a clinician dashboard, doctors can track patient data and symptom progression and flag patients with worsening symptoms, both inside and outside of clinical settings. Patients are able to use a corresponding mobile phone app to securely share personal health data such as temperature, respiration rate and heart rate.

The company’s RPM software is CE marked and under FDA enforcement discretion, and is ready to be deployed across the EU, US, China, Singapore, Hong Kong and Saudi Arabia.

Chelsea and Westminster Foundation Trust senior project manager for digital innovation Felix Vaal said: “During the Covid-19 crisis, Medopad’s solution can allow hospitals to continuously monitor and engage with their patients without the need to bring them into the healthcare system where there is an elevated risk of them contracting Covid-19.”

Medopad is also working with its global partners, including Johns Hopkins and Tencent, to clinically validate digital biomarkers to identify individual patient risk for Covid-19 and monitor respiratory symptoms and disease progression.

The includes developing a way to use a smartphone’s gyroscope-powered motion sensors to accurately measure an individual’s heart and respiratory rate without the need for additional hardware by placing a phone on the patient’s chest wall for 30-60 seconds.

Johns Hopkins Bloomberg School of Public Health associate professor Alain Labrique said: “We have been working in collaboration with Medopad for over a year on a digital biomarker project. Covid-19 presents an opportunity for us to take this work further and develop a specific Covid-19 digital biomarker. The aim is to adjust the data points collected and focus specifically on cardio-respiratory diseases, diabetes and other conditions which compromise the immune system to identify those who are most at risk should they contract Covid-19.”